(All figures are presented in U.S. dollars) Cash on hand grew by $4.6 million to $33.4 million EPS increased 25% year-over-year to $0.10 Adjusted EBITDA1 of $3.2 million was higher than Q1 2022...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the first quarter of 2023 on Thursday, May 11, 2023. The Company...

Mississauga, Ontario--(Newsfile Corp. - April 18, 2023) - Cipher Pharmaceuticals (TSX: CPH), a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage...

(All figures are in U.S. dollars) Product revenue increased 9% to $12.5 million in 2022 EBITDA of $12.0 million, relatively flat YoY Cash at December 31, 2022 was $28.8 million (CDN$39 million) or...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the three and twelve months ended December 31, 2022 after market...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced completion and closing of a new credit facility (the "Credit Facility") with Royal Bank of Canada (RBC). The...

(All figures are presented in U.S. dollars) EPS increased YoY by $0.08 to $0.11 in the third quarter; Strengthened balance sheet and demonstrated continued positive cash flow, ending Q3 with $27.5...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q3 2022 financial results on Thursday, November 10, 2022 after market close. The company...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to...

Experienced finance executive Bryan Jacobs, CPA, CA to join the Company as CFO, effective August 15, 2022. OAKVILLE, ON, Aug. 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or...

(All figures are in U.S. dollars) Drove 7% increase in product revenue to $3.5 million Generated $3.6 million in Adjusted EBITDA Total operating expenses declined 5% to $2.2 million Strong balance...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q2 2022 financial results on Thursday, August 11, 2022 after market close. The Company...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before...

(All figures are in U.S. dollars) Drove 60% increase in EPS to $0.08 Demonstrated a focus on execution as EBITDA increased 38% to $3.1 million Total operating expenses declined 25% to $2.5 million...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q1 2022 financial results on Thursday, May 12, 2022 after market close. The Company will...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that the Company's partner, Moberg Pharma AB, ("Moberg Pharma") has submitted a regulatory filing for the next...

Demonstrated growth in FY 2021 as EBITDA increased 46% to $11.8 million Disciplined cost structure led to an 18% reduction in SG&A 81% increase in EPS to $0.29 in FY2021 Strengthened cash flow...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial and operating results for the three and twelve months ended December 31, 2021...

Royalty agreement granting Sun Pharmaceutical Industries Inc. exclusive right to market, sell and distribute Absorica, Absorica AG and Absorica LD in the U.S. extended through December 31, 2026...

Revenue for nine months ended September 30, 2021increases 4.1% to $16.1 million Adjusted EBITDA1 for nine months ended September 30, 2021 increases to $9.8 million Basic EPS for the nine months ended

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q3 2021 financial results on Thursday, November 11, 2021. The company will hold a...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to renew...

Revenue increases 30% to $6.1 million, Adjusted EBITDA2 increases 40% to $4.1 million EPS increases 450% to $0.11 (CDN$0.141) Epuris revenue grows 63%, Absorica revenue grows 25% All figures in...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q2 2021 financial results on Thursday, August 12, 2021. The company will hold a conference...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier today. A...